Insulin prices shift unexpectedly due to behind-the-scenes formulary moves and rebate deals

Patients often face sudden increases in insulin costs, not from coverage changes, but due to complex formulary revisions and rebate arrangements overseen by pharmacy benefit managers, highlighting opaque drug pricing practices.

Many people are startled when the price of insulin at the pharmacy changes even though their insurance card has not. The reason is often not a switch in health plan, but a series of quieter changes behind the scenes: a revised formulary, a new rebate arrangement, a deductible resetting at the start of the year, or a different preferred product selected by a pharmacy benefit manager. For patients, the result can feel abrupt and unexplained.

A plan’s drug list is not fixed for the full year. Insurers and pharmacy benefit managers regularly review which medicines they will place on preferred tiers, and those decisions can alter what a patient owes at the counter. Diabetes advocacy groups have long warned that these annual contracting cycles can move insulin to a less favourable tier or replace one brand with another, changing the out-of-pocket price without changing the underlying insurance policy. The medicine may work just as well, but the coverage rules around it may have shifted.

Pharmacy benefit managers sit at the centre of much of this complexity. They negotiate rebates with manufacturers, steer drugs towards particular formulary positions and influence the terms that determine what patients ultimately pay. Recent Federal Trade Commission scrutiny of the largest PBMs has also focused attention on rebate practices and the extent to which they may have helped keep insulin list prices elevated, even as some savings were supposed to flow through to consumers. That has left patients navigating a system in which the sticker price, the negotiated price and the final copay are often very different things.

That disconnect helps explain why two people with the same insulin prescription can pay radically different amounts. A copay may be linked to a drug’s tier, a deductible, a coinsurance formula or a plan’s own reimbursement structure, rather than the manufacturer’s list price. Employers and insurers can design these benefits differently, so a prescription that is affordable for one patient may be far more expensive for another, even when the medicine and pharmacy are identical.

The rules also differ sharply between Medicare and private coverage. Medicare beneficiaries now generally pay no more than $35 for a one-month supply of covered insulin, with no deductible required, under provisions tied to the Inflation Reduction Act. Medicare.gov says that cap applies to insulin covered under Part B for pump users as well as under Part D for other covered insulin products. By contrast, private plans do not follow a single national cap, although some employers and states have introduced their own limits.

If insulin suddenly costs more, experts say the first step is to check whether the medicine is still preferred under the plan’s current formulary and whether the deductible has reset. Pharmacists may be able to identify a covered alternative, but any switch should be discussed with the prescribing clinician because insulin products are not always interchangeable. Manufacturers may also offer savings cards or patient assistance schemes for those who qualify. The broader lesson is that a higher bill does not automatically mean coverage has vanished; often, it means the machinery of drug pricing has shifted underneath the patient.